Sanofi terminates Phase III CIPD trial due to low efficacy
Sanofi is terminating a Phase III chronic inflammatory demyelinating polyneuropathy (CIDP) trial of riliprubart after analysis showed the drug is…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead Sciences and MSD’s human immunodeficiency virus (HIV) once weekly tablet combination has met primary endpoints in two Phase III…
-
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a…
-
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026. While…
-
Otsuka’s Voyxact preserves kidney function at 12 months
Otsuka Pharmaceutical’s Voyxact (sibeprenlimab-szsi) has preserved kidney function for 12 months in patients with primary IgA nephropathy (IgAN) in a…
-
Argenx’s Vyvgart shows durability in myositis and Sjögren’s
Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts. The…
-
EMA and AMA collaborate on Ebola trials amid public health emergency
The European Medicines Agency’s (EMA’s) emergency task force (ETF) is engaging with the African Medicines Agency (AMA) to plan clinical…
-
Rezolute’s stock up on interim Phase III tumour HI data
Rezolute’s second Phase III trial of ersodetug, this time in tumour hyperinsulinism (HI), is yielding more promising data, prompting the company’s…
-
ASCO26: In vivo oncology approaches continue to show promise
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting…
-
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
During the American Society of Clinical Oncology (ASCO) meeting 2026, data were presented for a number of cancer vaccines, including…